These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 31687820)

  • 1. Discovery of Novel Small Molecule Dual Inhibitors Targeting Toll-Like Receptors
    Padilla-Salinas R; Anderson R; Sakaniwa K; Zhang S; Nordeen P; Lu C; Shimizu T; Yin H
    J Med Chem; 2019 Nov; 62(22):10221-10244. PubMed ID: 31687820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preliminary evaluation of a 3H imidazoquinoline library as dual TLR7/TLR8 antagonists.
    Shukla NM; Malladi SS; Day V; David SA
    Bioorg Med Chem; 2011 Jun; 19(12):3801-11. PubMed ID: 21620714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of M5049: A Novel Selective Toll-Like Receptor 7/8 Inhibitor for Treatment of Autoimmunity.
    Vlach J; Bender AT; Przetak M; Pereira A; Deshpande A; Johnson TL; Reissig S; Tzvetkov E; Musil D; Morse NT; Haselmayer P; Zimmerli SC; Okitsu SL; Walsky RL; Sherer B
    J Pharmacol Exp Ther; 2021 Mar; 376(3):397-409. PubMed ID: 33328334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification and characterization of a novel chemotype for human TLR8 inhibitors.
    Šribar D; Grabowski M; Murgueitio MS; Bermudez M; Weindl G; Wolber G
    Eur J Med Chem; 2019 Oct; 179():744-752. PubMed ID: 31284084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification and validation of a novel dual small-molecule TLR2/8 antagonist.
    Grabowski M; Bermudez M; Rudolf T; Šribar D; Varga P; Murgueitio MS; Wolber G; Rademann J; Weindl G
    Biochem Pharmacol; 2020 Jul; 177():113957. PubMed ID: 32268138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The functional effects of physical interactions among Toll-like receptors 7, 8, and 9.
    Wang J; Shao Y; Bennett TA; Shankar RA; Wightman PD; Reddy LG
    J Biol Chem; 2006 Dec; 281(49):37427-34. PubMed ID: 17040905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toll-like receptor (TLR)-7 and -8 modulatory activities of dimeric imidazoquinolines.
    Shukla NM; Mutz CA; Malladi SS; Warshakoon HJ; Balakrishna R; David SA
    J Med Chem; 2012 Feb; 55(3):1106-16. PubMed ID: 22239408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small-molecule inhibition of TLR8 through stabilization of its resting state.
    Zhang S; Hu Z; Tanji H; Jiang S; Das N; Li J; Sakaniwa K; Jin J; Bian Y; Ohto U; Shimizu T; Yin H
    Nat Chem Biol; 2018 Jan; 14(1):58-64. PubMed ID: 29155428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Target-Based Identification and Optimization of 5-Indazol-5-yl Pyridones as Toll-like Receptor 7 and 8 Antagonists Using a Biochemical TLR8 Antagonist Competition Assay.
    Knoepfel T; Nimsgern P; Jacquier S; Bourrel M; Vangrevelinghe E; Glatthar R; Behnke D; Alper PB; Michellys PY; Deane J; Junt T; Zipfel G; Limonta S; Hawtin S; Andre C; Boulay T; Loetscher P; Faller M; Blank J; Feifel R; Betschart C
    J Med Chem; 2020 Aug; 63(15):8276-8295. PubMed ID: 32786235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual or triple activation of TLR7, TLR8, and/or TLR9 by single-stranded oligoribonucleotides.
    Forsbach A; Samulowitz U; Völp K; Hofmann HP; Noll B; Tluk S; Schmitz C; Wader T; Müller C; Podszuweit A; Lohner A; Curdt R; Uhlmann E; Vollmer J
    Nucleic Acid Ther; 2011 Dec; 21(6):423-36. PubMed ID: 22196370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small-Molecule TLR8 Antagonists via Structure-Based Rational Design.
    Hu Z; Tanji H; Jiang S; Zhang S; Koo K; Chan J; Sakaniwa K; Ohto U; Candia A; Shimizu T; Yin H
    Cell Chem Biol; 2018 Oct; 25(10):1286-1291.e3. PubMed ID: 30100350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of potent, orally bioavailable in vivo efficacious antagonists of the TLR7/8 pathway.
    Alper PB; Deane J; Betschart C; Buffet D; Collignon Zipfel G; Gordon P; Hampton J; Hawtin S; Ibanez M; Jiang T; Junt T; Knoepfel T; Liu B; Maginnis J; McKeever U; Michellys PY; Mutnick D; Nayak B; Niwa S; Richmond W; Rush JS; Syka P; Zhang Y; Zhu X
    Bioorg Med Chem Lett; 2020 Sep; 30(17):127366. PubMed ID: 32738975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toll-like receptor 7 and 8 imidazoquinoline-based agonist/antagonist pairs.
    Yang M; Larson PG; Brown L; Schultz JR; Kucaba TA; Griffith TS; Ferguson DM
    Bioorg Med Chem Lett; 2022 Mar; 59():128548. PubMed ID: 35051578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The TLR7/8 ligand resiquimod targets monocyte-derived dendritic cell differentiation via TLR8 and augments functional dendritic cell generation.
    Hackstein H; Knoche A; Nockher A; Poeling J; Kubin T; Jurk M; Vollmer J; Bein G
    Cell Immunol; 2011; 271(2):401-12. PubMed ID: 21889130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and immunological activities of novel Toll-like receptor 7 and 8 agonists.
    Kandimalla ER; Struthers M; Bett AJ; Wisniewski T; Dubey SA; Jiang W; Precopio M; Sun Z; Wang H; Lan T; Agrawal S; Casimiro DR
    Cell Immunol; 2011; 270(2):126-34. PubMed ID: 21570062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of High-Potency Human TLR8 and Dual TLR7/TLR8 Agonists in Pyrimidine-2,4-diamines.
    Beesu M; Salyer AC; Brush MJ; Trautman KL; Hill JK; David SA
    J Med Chem; 2017 Mar; 60(5):2084-2098. PubMed ID: 28146629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TLR7/8 agonists activate a mild immune response in rabbits through TLR8 but not TLR7.
    Lai CY; Liu YL; Yu GY; Maa MC; Leu TH; Xu C; Luo Y; Xiang R; Chuang TH
    Vaccine; 2014 Sep; 32(43):5593-9. PubMed ID: 25131730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective Toll-like receptor 7 agonists with novel chromeno[3,4-d]imidazol-4(1H)-one and 2-(trifluoromethyl)quinoline/ quinazoline-4-amine scaffolds.
    Dolšak A; Švajger U; Lešnik S; Konc J; Gobec S; Sova M
    Eur J Med Chem; 2019 Oct; 179():109-122. PubMed ID: 31247373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toll-like receptor 8 deletion accelerates autoimmunity in a mouse model of lupus through a Toll-like receptor 7-dependent mechanism.
    Tran NL; Manzin-Lorenzi C; Santiago-Raber ML
    Immunology; 2015 May; 145(1):60-70. PubMed ID: 25424423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of TLR7/8 small RNA antagonists.
    Sioud M
    Methods Mol Biol; 2010; 629():387-94. PubMed ID: 20387163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.